by David Cassak
There was a time—and really not all that long ago—when the orthopedics industry, and in particular, the total joint replacement...
Long a pioneer in prosthetics, one of orthopedics' forgotten spaces, Stanmore Implants Worldwide, has a new investor group who hope to transform this once academic supplier into a thriving orthopedics player by focusing on specialty niches that the Ortho giants have largely ignored.
by David Cassak
There was a time—and really not all that long ago—when the orthopedics industry, and in particular, the total joint replacement...
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.